Publicaciones científicas
- [TERAPIAS AVANZADAS PARA ENFERMEDADES HEPÁTICAS RARAS]
- [HEMATO-ONCOLOGÍA]
- [HEMATOLOGÍA TRASLACIONAL]
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)
Fermín Sánchez-Guijo 1 , Cristina Avendaño-Solá 2 , Lina Badimón 3 , Juan A Bueren 4 , Josep M Canals 5 6 , Joaquim Delgadillo 7 , Julio Delgado 8 , Cristina Eguizábal 9 , María-Eugenia Fernández-Santos 10 , Damián García-Olmo 11 , Gloria González-Aseguinolaza 12 , Manel Juan 8 , Francisco Martín 13 14 , Rosario Mata 15 , Nuria Montserrat 16 17 , Antonio Pérez-Martínez 18 , José A Pérez-Simón 19 , Felipe Prósper 20 , Álvaro Urbano-Ispizua 8 , Agustín G Zapata 21 , Anna Sureda 22 , José M Moraleda 23
The Hospital Exemption rule is considered a valuable European legislative initiative that guarantees patient access to novel therapies based on the use of advanced therapy medicinal products (ATMPs) in the Member States.
On the occasion of the update of the European General Pharmaceutical Legislation, the Spanish Network of Advanced Therapies (TERAV, formerly TerCel), which has played a recognized leadership in Europe in the development of both academic and pharmaceutically commercialized ATMPs [1], would like to make the following position statement...
CITA DEL ARTÍCULO Bone Marrow Transplant. 2023 Mar 25. doi: 10.1038/s41409-023-01962-0
Nuestros autores
